| Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation GT Wong, D Manfra, FM Poulet, Q Zhang, H Josien, T Bara, L Engstrom, ... Journal of Biological Chemistry 279 (13), 12876-12882, 2004 | 922 | 2004 |
| The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients ME Kennedy, AW Stamford, X Chen, K Cox, JN Cumming, MF Dockendorf, ... Science translational medicine 8 (363), 363ra150-363ra150, 2016 | 454 | 2016 |
| Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. EM Parker, K Kameyama, T Higashijima, EM Ross Journal of Biological Chemistry 266 (1), 519-527, 1991 | 401 | 1991 |
| Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells EM Parker, DG Izzarelli, HP Nowak, CD Mahle, LG Iben, J Wang, ... Molecular brain research 34 (2), 179-189, 1995 | 293 | 1995 |
| Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. SK Wong, EM Parker, EM Ross Journal of Biological Chemistry 265 (11), 6219-6224, 1990 | 281 | 1990 |
| MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition MJ Fell, C Mirescu, K Basu, B Cheewatrakoolpong, DE DeMong, JM Ellis, ... Journal of Pharmacology and Experimental Therapeutics 355 (3), 397-409, 2015 | 258 | 2015 |
| The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a … GB Varty, M Grilli, A Forlani, S Fredduzzi, ME Grzelak, DH Guthrie, ... Psychopharmacology 179, 207-217, 2005 | 181 | 2005 |
| Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2, 4-difluorophenyl]-1-piperazinyl] ethyl]-2-(2-furanyl)-7H … RA Hodgson, R Bertorelli, GB Varty, JE Lachowicz, A Forlani, S Fredduzzi, ... Journal of Pharmacology and Experimental Therapeutics 330 (1), 294-303, 2009 | 169 | 2009 |
| Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. EM Parker, LX Cubeddu Journal of Pharmacology and Experimental Therapeutics 245 (1), 199-210, 1988 | 169 | 1988 |
| Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: Part I Inhibitor design and validation Z Zhu, ZY Sun, Y Ye, J Voigt, C Strickland, EM Smith, J Cumming, L Wang, ... Journal of medicinal chemistry 53 (3), 951-965, 2010 | 165 | 2010 |
| Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel μM leads for the development … YS Wang, C Strickland, JH Voigt, ME Kennedy, BM Beyer, MM Senior, ... Journal of medicinal chemistry 53 (3), 942-950, 2010 | 156 | 2010 |
| Discovery of the 3-imino-1, 2, 4-thiadiazinane 1, 1-dioxide derivative verubecestat (MK-8931)–a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment … JD Scott, SW Li, APJ Brunskill, X Chen, K Cox, JN Cumming, M Forman, ... Journal of medicinal chemistry 59 (23), 10435-10450, 2016 | 155 | 2016 |
| Activation of the NPY Y5 receptor regulates both feeding and energy expenditure JJ Hwa, MB Witten, P Williams, L Ghibaudi, J Gao, BG Salisbury, ... American Journal of Physiology-Regulatory, Integrative and Comparative …, 1999 | 154 | 1999 |
| Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor JN Cumming, EM Smith, L Wang, J Misiaszek, J Durkin, J Pan, U Iserloh, ... Bioorganic & medicinal chemistry letters 22 (7), 2444-2449, 2012 | 150 | 2012 |
| Bioprinted 3D primary human intestinal tissues model aspects of native physiology and ADME/Tox functions LR Madden, TV Nguyen, S Garcia-Mojica, V Shah, AV Le, A Peier, ... IScience 2, 156-167, 2018 | 145 | 2018 |
| Identification of potent and selective neuropeptide Y Y1 receptor agonists with orexigenic activity in vivo D Mullins, D Kirby, J Hwa, M Guzzi, J Rivier, E Parker Molecular pharmacology 60 (3), 534-540, 2001 | 136 | 2001 |
| Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice NB Hastings, X Wang, L Song, BD Butts, D Grotz, R Hargreaves, ... Molecular Neurodegeneration 12, 1-16, 2017 | 133 | 2017 |
| Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats JJ Hwa, L Ghibaudi, J Gao, EM Parker American Journal of Physiology-Regulatory, Integrative and Comparative …, 2001 | 131 | 2001 |
| Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status E Parker, M Van Heek, A Stamford European journal of pharmacology 440 (2-3), 173-187, 2002 | 127 | 2002 |
| Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. II. Release in the presence of vesicular transmitter … EM Parker, LX Cubeddu Journal of Pharmacology and Experimental Therapeutics 237 (1), 193-203, 1986 | 127 | 1986 |
